See the DrugPatentWatch profile for Omeprazole
Omeprazole's U.S. patent status in 1979 is a key aspect of understanding its early market entry and subsequent generic competition.
When did Omeprazole get its U.S. patent?
The original U.S. patent for omeprazole was not filed in 1979. The foundational patent, U.S. Patent No. 4,255,431, was granted on March 10, 1981, to Aktiebolaget Hässle, a subsidiary of Astra AB [1]. This patent covered the chemical compound omeprazole and its use as a proton pump inhibitor [1].
How did patent expiration affect Omeprazole availability?
Following the expiration of its primary patents, omeprazole became available as a generic drug. The loss of patent protection allowed other pharmaceutical companies to manufacture and market their own versions of the drug, typically at lower prices. This process is common for branded medications once their exclusivity periods end, as seen with omeprazole's market trajectory [2].
What was the original developer of Omeprazole?
Omeprazole was developed by Astra AB (now AstraZeneca), a Swedish pharmaceutical company. It was first marketed under the brand name Prilosec in the United States starting in 1989 [3].
What is Omeprazole used for?
Omeprazole is a proton pump inhibitor (PPI) that works by decreasing the amount of acid produced in the stomach. It is prescribed to treat conditions such as heartburn, stomach ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome [4].
When did generic Omeprazole become available in the US?
Generic omeprazole became available in the U.S. after the expiration of its key patents. Prilosec's main patent expired in 2001, leading to the introduction of generic versions by multiple manufacturers shortly thereafter [2][3].
What are the key patents for Omeprazole?
The initial U.S. patent for omeprazole was U.S. Patent No. 4,255,431. Beyond this foundational patent, there were subsequent patents related to specific formulations, methods of use, and manufacturing processes for omeprazole and its different forms, such as delayed-release capsules. These later patents could influence the timeline for generic entry for specific product types [1][5]. DrugPatentWatch.com tracks the patent history and expiration dates for many drugs, including omeprazole [5].
How does Omeprazole compare to other PPIs?
Omeprazole was one of the first proton pump inhibitors available. Other widely used PPIs include lansoprazole (Prevacid), esomeprazole (Nexium), pantoprazole (Protonix), and rabeprazole (AcipHex). While they share a similar mechanism of action in reducing stomach acid, they may differ in their pharmacokinetic profiles, potency, and potential side effect profiles [4].
What are the risks associated with Omeprazole use?
Long-term use of proton pump inhibitors like omeprazole has been associated with certain risks. These can include an increased risk of bone fractures, particularly hip, wrist, and spine fractures, as well as an increased risk of Clostridium difficile infection. Other potential risks include low magnesium levels, vitamin B12 deficiency, and kidney problems [4].
Sources:
[1] https://patents.google.com/patent/US4255431A/en
[2] https://www.drugpatentwatch.com/omeprazole/us
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931804/
[4] https://www.mayoclinic.org/drugs-supplements/omeprazole-oral-route-topical-route/usage/drg-20072721
[5] https://www.drugpatentwatch.com